SURGICEL Absorbable Hemostats
ETHICON, Inc. · Decision date Nov 4, 2025
What did the FDA approve?
FDA records N12159/S122 as a supplement to PMA null, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 4, 2025.
FDA approval order statement
approval for qualification of the use of the SURGICEL FIBRILLAR (hereafter called as Surgicel Fibrillar) material to produce SURGICEL Powder Absorbable Haemostatic Powder (hereafter called as Surgicel Powder) manufacturing at Ethicon, LLC, San Lorenzo, Puerto Rico facility.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Nov 4, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- N12159/S122
- Regulatory pathway
- PMA supplement
- Applicant
- ETHICON, Inc.
- Product code
- LMG
- Decision code
- APPR
- Decision date
- Nov 4, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, non-collagen based.
- Applicant
- ETHICON, Inc.
- Product code
- LMG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N12159/S122 received
Application receipt date recorded by FDA.
N12159/S122 · FDA decision
Real-Time Process
Related devices and submissions
Explore the linked device profile
Other records with product code LMG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Baxter Healthcare Corporation | PMA supplement | Nov 7, 2026 | FDA | |
SURGICEL Absorbable HemostatsN12159/S132 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
PerClot Polysaccharide Hemostatic SystemP210036/S008 | Baxter Healthcare Corporation | PMA supplement | Aug 7, 2026 | FDA |
PerClot Polysaccharide Hemostatic SystemP210036/S009 | Baxter Healthcare Corporation | PMA supplement | Aug 7, 2026 | FDA |
| ETHICON, Inc. | PMA supplement | Jul 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ETHICON, Inc.
- Headquarters
- Not reported
- Brand website
- ethicon.com
- FDA applicant address
- 1000 Rte. 202, Raritan, NJ, 08869
Sources and methodology
- Original FDA record: N12159/S122
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records